A review article published on the journal Oncotarget focusing on RB role in apoptosis provides a comprehensive overview on the role of RB proteins in the coordinated control of cell decisions.
The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients. A "Perspectives" article in the July 2 issue of The New England Journal of Medicine proposes that placebo effects be more broadly defined to reflect their role as a valuable component of medical care.
Researchers from the Icahn School of Medicine at Mount Sinai have discovered that histones are steadily replaced in brain cells throughout life
Long-term use of naproxen (ALEVE), a type of nonsteroidal anti-inflammatory drug (NSAID), is often prescribed for chronic pain conditions such as osteoarthritis. However, because of NSAID-related gastrointestinal problems including stomach and intestinal inflammation and ulcers, many are unable to tolerate ongoing use. A new study, published in the American Journal of Physiology–Gastrointestinal and Liver Physiology, finds that a naproxen-derivative may provide both symptom relief and gastrointestinal protection. The research is highlighted as one of this month’s “best of the best” as part of the American Physiological Society’s APSselect program.
St John’s Wort can produce the same adverse reactions as antidepressants, and serious side effects can occur when the two are taken together, according to new University of Adelaide research.
The Food and Drug Administration (FDA) announced today that it will delay enforcement of Track and Trace requirements that were scheduled to go into effect on July 1, 2015, until November 1, 2015. This policy change follows a formal written request by ASHP urging FDA to give hospitals and health systems more time to comply with the regulations.
Vermont scientists have invented a new technique for discovering potentially dangerous drug interactions--before they show up in medical databases like PubMed--by searching millions of tweets on Twitter.
For the first time, researchers have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Other topics include weight loss, medical marijuana, smart traffic lights, diabetes, heart disease, and more.
Other topics include dietary guidelines, smart traffic lights, breast cancer, and biomarker tests for cancer treatment.
Monte Shaheen, MD, and colleagues from around the country recently published a paper in the New England Journal of Medicine about a promising new treatment for melanoma.
A rigorous analysis of more than 20,000 medical records concludes that erectile dysfunction drugs, such as Viagra, are not a cause of melanoma, an often deadly form of skin cancer, despite the higher risk for the disease among users of these drugs.
Among men in Sweden, use of erectile dysfunctions drugs with phosphodiesterase type 5 inhibitors was associated with a modest but significant increased risk of malignant melanoma, although the pattern of association raises questions about whether this association is causal, according to a study in the June 23/30 issue of JAMA.
A series of fascinating studies at Harvard University showed that many people respond positively to placebo pills — even when they are told that the pills don't have any active ingredients. Researchers at UAB are partnering with a Harvard scientist to test these "open-label" placebos for the first time among cancer survivors.
Patients with atrial fibrillation who stopped taking blood thinners before they had elective surgery had no higher risk of developing blood clots and less risk of major bleeding compared to patients who were given a “bridge” therapy, according to research led by Duke Medicine.
CGRP monoclonal antibodies appear to significantly reduce the frequency of migraine in human clinical trials, potentially changing the landscape for migraine treatment. Headache specialist Sid Kapoor, MD, discusses the enormous potential -- and pitfalls-- facing the drug class' road to FDA approval.
Topics include: treating advanced skin cancer, big data and bioenergy, cancer research, 10 reasons to eat quinoa, sleep issues in the nursing field, advances in cancer surgery, genes for sleep, brain receptor for cocaine addiction, and nano imaging on insect adaptations.
You can whack it with a hammer, attack it with a drill, or even stab it with a screwdriver. But try as you might, you won’t be able to get into this pill dispenser. Which is exactly the idea.
Scientists at The Scripps Research Institute have teamed up with several other institutions and pharmaceutical companies, to publish the first 3D structures of a receptor implicated in many diseases of the brain and in normal physiology throughout the body.
Researchers at University of California, San Diego School of Medicine have made a surprisingly simple discovery: The modification of more than 100 secreted proteins is the work of a single enzyme called Fam20C. The finding is published June 18 by Cell.
Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients. The results revealed two genes that could help physicians make more informed treatment decisions for patients with this disease.
Trending news releases with the most views in a single day. Topics include: An anonymous donor for cancer research, solar storms and incidences of rheumatoid arthritis, vulnerabilities in genome’s ‘Dimmer Switches’, new treatments for Alzheimer's, How people make decisions for or against flu vaccinations.
Trending news releases with the most views in a single day. Topics include: new drug for heart disease, astronomy, sleep, stroke, diabetes, materials science, MERS, and U.S. Politics.
A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.
According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving – often referred to as executive functions – related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).
In clinical trials, a new drug class known as PCSK9 Inhibitors reduced bad cholesterol markedly and is expected to be approved by the FDA this summer. An expert in lipid management discusses some of the barriers to its use.
In a study published in Science June 12, Case Western Reserve and University of Texas-Southwestern researchers detail how a new drug repaired damage to the colon, liver and bone marrow in animal models — even saving mice who otherwise would have died in a bone marrow transplantation model.
Adults who use proton pump inhibitors are between 16 and 21 percent more likely to experience a heart attack than people who don't use the commonly prescribed antacid drugs, according to a massive new study by Houston Methodist and Stanford University scientists.
It started out as a treatment for arthritis. But steered by science, it could become a first new approach in two decades for treating the damage that diabetes inflicts on the kidneys of millions of people.
Dr. Charles H. Hennekens has done ground-breaking research on the benefits of statins, aspirin, ACE inhibitors, ARBs as well as beta adrenergic blockers. His guidance will assist clinicians to address the clinical and public health challenges to increase utilization of statins in the treatment and prevention of heart attacks and strokes.
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.
Sheryl Kingsberg, PhD, is available for comment about flibanserin. Video package with sound bites available.
It may be better for patients to resume taking their blood pressure medication sooner after surgery than previously thought. A new study published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists® (ASA®), found resuming angiotensin receptor blockers (ARBs), common medications used to treat high blood pressure, within two days after surgery decreased death rates in the first month following surgery.
An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies. PPHN is a rare but life-threatening condition that occurs when a newborn's circulation system doesn't adapt to breathing outside the womb.
Trending news releases with the most views in a single day. Topics include: neurology, cancer, immunotherapy, Alan Alda present science award, genetics, vision, lung cancer, prostate cancer, environmental health.
Few heart specialists make use of published information about interactions between drugs used to treat cardiovascular disease and the genetic variations that affect how patients respond to them. So physicians at U Chicago and Stanford combed through the literature on the pharmacogenomics of the leading cardiovascular drugs and compiled summaries.
A large cooperative-group study has confirmed previous evidence that lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with the disease.
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. These findings were presented today at the 2015 ASCO Annual Meeting in Chicago. The benefit reported in this trial appeared later in follow up of the women in the study.
The importance of preventing hypertension is reinforced by a study showing anti-hypertension medicines can increase stroke risk by 248 percent, according to new UAB School of Public Health research published in the journal Stroke.
If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined.
A new report from UAB demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, proposes race-specific equations to help clinicians better calculate warfarin dosage.
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago. Their findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. Preclinical studies suggest that JAK2 inhibitors may be an effective treatment option for CMML. Eric Padron, M.D., assistant member of the Malignant Hematology Program at Moffitt Cancer Center will report on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago
Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention – the use of agents to prevent the development or progression of prostate cancer. A team of researchers led by Nagi B. Kumar, Ph.D., R.D., F.A.D.A. at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men who have premalignant lesions. The results will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Trending news releases with the most views in a single day. Topics include: income inequality, climate change, genetics, cancer, precision medicine, medical imaging, schizophrenia, research funding, molecular biology and skin cancer.
For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells. The drug has been approved for use in patients in Europe and is in clinical trials in the U.S.
Trending news releases with the most views in a single day. Topics include: genetics and cancer, diabetes and blindness, nanotech, engineering, personalized medicine, energy, and e-cigarettes.
New research has led to FDA approval of the use of a drug to treat the effects of radiation exposure following a nuclear incident. The drug, Neupogen, is the first ever approved for the treatment of acute radiation injury.
Chemists at The Scripps Research Institute have discovered a broad, strikingly inexpensive method for synthesizing “amines,” a class of organic compounds prominent in drugs and other modern products. The new reaction is particularly useful for synthesizing complex amines valuable in pharmaceuticals, but impractical—or impossible—to make with standard methods.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right